ArticleExperimental hematology & oncology2020

Two-year long safety and efficacy of deferasirox film-coated tablets in patients with thalassemia or lower/intermediate risk MDS: phase 3 results from a subset of patients previously treated with deferasirox in the ECLIPSE study.

Immacolata Tartaglione et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.